Published Online
on October 10, 2005

A more recent version of this article appeared on November 1, 2005

This Article Full Text (PDF) All Versions of this Article: 46/5/1093    most recent 01.HYP.0000184652.93583.77v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strawn, W. B. Search for Related Content PubMed PubMed Citation Articles by Strawn, W. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SPIRONOLACTONE Related Collections Pathophysiology Risk Factors Related Article

Eplerenone Antagonizes Atherosclerosis, But What Is the Agonist?

William B. Strawn^*

From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

^* To whom correspondence should be addressed. E-mail: bstrawn{at}wfubmc.edu.

Related Article:

Eplerenone Inhibits Atherosclerosis in Nonhuman Primates

Shinji Takai, Denan Jin, Michiko Muramatsu, Kazuyoshi Kirimura, Hiroshi Sakonjo, and Mizuo Miyazaki
Hypertension 2005 46: 1135-1139. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				D. Armanini, C. Fiore, L. A Calo, S. Takai, and M. Miyazaki Mononuclear Leukocyte Mineralocorticoid Receptors * Response Hypertension, February 1, 2006; 47(2): e4 - e5. [Full Text] [PDF]